Meet the Ignyta Management Team

This team is working toward the bold goal of eradicating residual disease in precisely defined patient populations by 2030.

Ignyta CEO and Co-Founder Jonathan E. Lim, M.D.

Jonathan E. Lim, M.D.

Chairman, CEO, and Co-Founder

Jonathan Lim co-founded Ignyta as Chairman in August 2011 and joined full-time in July 2012 as President and Chief Executive Officer. Under his leadership, the company went public in 2013. It has raised nearly $350 million from financings and corporate transactions with Teva and Lilly and is focused on building a precision medicine company aspiring to eradicate residual disease in precisely defined cancer patient populations by 2030.

From May 2003 to December 2010, Dr. Lim was President, Chief Executive Officer, and a Director of Halozyme Therapeutics, Inc. (NASDAQ: HALO). In March 2011, Dr. Lim co-founded and most recently served as Chairman and CEO of Eclipse Therapeutics, a Biogen Idec spinout. Eclipse was successfully sold to Bionomics Ltd. (ASX:BNO) in a transaction that closed in September 2012, and Dr. Lim subsequently served as a member of the Board of Directors of Bionomics for three years, until November 2015. He is also a member of the Board of Visitors of the Moores Cancer Center at UC San Diego, a position he has held since December 2015, and an Advisory Council member of Stanford Bio-X, an initiative by Stanford University to foster interdisciplinary medical research. In February 2016, Dr. Lim joined the Board and currently serves as Chairman of Bonti, Inc., a startup developing next-generation neurotoxins for patients with unmet needs in post-surgical care and aesthetic medicine.

Dr. Lim’s prior experience also includes management consulting at McKinsey & Company, an NIH Postdoctoral Fellowship at Harvard Medical School and the Dana Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center.

He has B.S. and M.S. degrees from Stanford, an M.D. from McGill, and an M.P.H. from Harvard.

Ignyta Chief Operating Officer Zachary Hornby

Zachary Hornby

Chief Operating Officer

Zachary Hornby brings a dozen years of life sciences business experience to Ignyta. Prior to joining Ignyta, Mr. Hornby was senior director of business development at Fate Therapeutics, where he was responsible for pharmaceutical partnerships and non-dilutive funding. Mr. Hornby has also served in various business and commercial roles at Halozyme Therapeutics (NASDAQ: HALO), Neurocrine Biosciences (NASDAQ: NBIX), and TKT (now Shire Human Genetic Therapies), and he was a life sciences consultant at L.E.K. Consulting. Mr. Hornby is a director of Independa, Inc.

Mr. Hornby holds B.S. and M.S. degrees in biology from Stanford University and an M.B.A. from Harvard Business School.

Ignyta Chief Financial Officer Jacob Chacko, M.D.

Jacob Chacko, M.D.

Chief Financial Officer

Jacob Chacko brings to Ignyta a broad range of experience with financing, managing, and advising companies in the life sciences field. Dr. Chacko joined Ignyta in May 2014 from TPG Capital, a global private investment firm with approximately $60 billion of assets under management, where he served as a Vice President focused primarily on healthcare and digital media since August 2008. At TPG, Dr. Chacko helped lead teams that successfully completed acquisitions having an aggregate value of over $10 billion. He served on the boards of directors of RentPath and EnvisionRx, was an advisor to the audit committee of Par Pharmaceutical, and was a board observer to IMS Health and Quintiles Transnational.

Prior to TPG, Dr. Chacko concurrently received his M.D. from UCLA and his M.B.A. from Harvard Business School, and he was president of his class at both institutions. Prior to this, Dr. Chacko was a consultant serving healthcare clients at the management consulting firm, McKinsey & Company.

Dr. Chacko also received an M.Sc. in economic and social history from Oxford University, where he was a Marshall Scholar, and a B.A. in biology, B.S. in gerontology, and minor in health policy and management from the University of Southern California.

Ignyta Senior VP of Chemistry Valerie Harding, Ph.D.

Valerie Harding, Ph.D.

Senior Vice President, Chemistry, Manufacturing and Controls

Dr. Harding brings to the company rich experience in pharmaceutical drug development and formulation. She joined the company in September 2015 from Pfizer, where she spent more than 25 years in positions of increasing responsibility, including Vice President of Product Differentiation, Vice President of Drug Product Design, and Vice President of Pharmaceutical Development.

Prior to Pfizer, Dr. Harding spent three years as a Scientist and team leader at Boots and Company, preceded by three years as a tutor and researcher at the University of Nottingham School of Pharmacy.

Dr. Harding holds a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham and a B.S. in Pharmacy from the University of London.

Ignyta General Counsel Christian Kuhlen, M.D.

Christian V. Kuhlen, M.D.

General Counsel

Christian V. Kuhlen joined Ignyta in July 2016, bringing extensive executive management, corporate legal, governance, M&A, and business development experience to the company. Dr. Kuhlen was previously Vice President, General Counsel and Secretary at Genoptix, Inc. (a Novartis company), a role he served in since 2007. At Genoptix, Dr. Kuhlen was responsible for all legal and corporate governance functions, including guiding the company through its initial public offering and follow-on offerings and subsequent sale to Novartis.

Prior to Genoptix, Dr. Kuhlen was an attorney with Cooley LLP focusing on the needs of public and private biotechnology companies, including financings, M&A, IP, licensing and corporate governance matters. Prior to medical school, he was a research assistant at The Scripps Research Institute in La Jolla, California.

Dr. Kuhlen holds a B.S. in biochemistry and cell biology and a B.A. in economics from UC San Diego, and a J.D. and M.D. from the University of Southern California.

Ignyta Chief Business Officer William McCarthy

William McCarthy

Chief Business Officer

William McCarthy joined the company in December 2015, bringing substantial experience in corporate and business development, new product planning, and alliance management. He was previously Vice President of Corporate and Business Development at Foundation Medicine, a position he held since April 2014. In this role, he was responsible for guiding FMI’s corporate development strategy, leading related strategic transactions, and overseeing FMI’s alliance with Roche Pharmaceuticals.

Prior to FMI, Mr. McCarthy held positions of increasing responsibility at Halozyme Therapeutics from 2007 to 2014, including Executive Director of Business Development and Senior Director of Marketing and New Product Planning. At Halozyme, Mr. McCarthy led several buy-side and sell-side strategic initiatives and transactions, and he also built and led the team responsible for commercial strategy for portfolio programs. From 2006 to 2007, Mr. McCarthy was Associate Director of Business Planning at Biogen Idec, and from 2005 to 2006, he was Associate Director of New Product Planning at Neurocrine Biosciences. Prior to Neurocrine, Mr. McCarthy spent ten years as a management consultant at IMS Consulting Group, Deloitte Consulting, and Cambridge Pharma Consultancy.

Mr. McCarthy holds an M.B.A. from London Business School and a B.A. in economics from the University of Exeter.

Ignyta Chief Medical Officer Pratik Multani, M.D.

Pratik S. Multani, M.D.

Chief Medical Officer

Pratik Multani joined Ignyta in February 2015, bringing to the company broad technical and management experience in clinical development and a deep understanding of oncology. Dr. Multani was previously Chief Medical Officer at Fate Therapeutics, where he served from April 2009 to January 2015. At Fate, Dr. Multani led the clinical development of ProHema for the treatment of hematologic malignancies and other rare diseases.

Prior to Fate, Dr. Multani was Vice President of Clinical Development at Kalypsys from 2007 to 2009, where he advanced the development of multiple targeted compounds across a broad range of indications, including pain, inflammation, and metabolic diseases. From 2005 to 2007, as Senior Vice President of Clinical Development and then Chief Medical Officer at Kanisa Pharmaceuticals, Dr. Multani led the Phase 2 and Phase 3 development of zosuquidar, along with a companion diagnostic, for the treatment of acute myeloid leukemia. From 2004 to 2005, Dr. Multani was Vice President of Clinical Development at Salmedix, where he led the clinical development of bendamustine, as well as other programs in hematologic malignancies and solid tumors. Dr. Multani held positions of increasing responsibility at Biogen Idec from 1999 to 2004, including Senior Director of Medical Research, where he led or provided strategic direction for multiple development and commercial-stage programs, including Zevalin® and Rituxan®.

Dr. Multani received a B.S. degree in chemistry and biology from Yale University and an M.D. from Harvard Medical School, followed by an M.S. degree in epidemiology at the Harvard School of Public Health. He completed his Internal Medicine residency at Massachusetts General Hospital and a medical oncology fellowship at the Dana Farber/Partners joint program. Before his career in industry, Dr. Multani held academic and clinical positions at Harvard Medical School and Massachusetts General Hospital, where he was a member of the bone marrow transplant unit.